Oekonomienobelpreisträger Joseph Stiglitz plädiert im British Medical Journal gegen Pharmapatente und für hochdotierte Forschungspreise als Alternative:

A medical prize fund provides an alternative. Such a fund would give large rewards for cures or vaccines for diseases like malaria that affect millions, and smaller rewards for drugs that are similar to existing ones, with perhaps slightly different side effects. The intellectual property would be available to generic drug companies. The power of competitive markets would ensure a wide distribution at the lowest possible price, unlike the current system, which uses monopoly power, with its high prices and limited usage.